CG Oncology (CGON) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
CG Oncology (CGON) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 64.2% versus a loss of 11.4%. Rhythm Pharmaceuticals is the larger company by market cap ($6.09 billion vs $5.53 billion), about 1.1 times the size, while CG Oncology is growing revenue faster (+254.7% vs +45.8%). Rhythm Pharmaceuticals converts more of its revenue into profit, with a net margin of -103.6% versus -3985.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | RYTM |
|---|---|---|
| Share price | $62.38 | $88.45 |
| Market cap | $5.53B | $6.09B |
| 1-day change | -1.98% | -2.56% |
| YTD return | +50.24% | -17.37% |
| 1-year return | +64.16% | -11.40% |
| 5-year return | — | +682.05% |
| EPS (TTM) | $-2.69 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $189.76M |
| Revenue growth (YoY) | +254.70% | +45.83% |
| Net income (latest FY) | $-161.00M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | -4722.13% | -101.19% |
| Net margin | -3985.02% | -103.57% |
| 52-week high | $80.97 | $122.20 |
| 52-week low | $35.80 | $74.50 |
| Distance from 52-week high | -22.96% | -27.62% |
| Analyst consensus | none | none |
| Avg. price target upside | +46.01% | +56.69% |
| Average volume | 899.28K | 646.31K |
| Shares outstanding | 88.64M | 68.85M |
| Employees | 142 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGON has outperformed RYTM by 75.6 percentage points over the past year.
- Rhythm Pharmaceuticals is more profitable, keeping -103.6 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs +45.83%).
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
CGON vs RYTM FAQ
Which is bigger, CG Oncology or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $6.09B compared with $5.53B for CG Oncology (CGON).
Which stock has performed better over the past year, CGON or RYTM?
CGON returned +64.16% over the past 12 months, compared with -11.40% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Rhythm Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for CG Oncology and Biotechnology: Pharmaceutical Preparations for Rhythm Pharmaceuticals.